Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT84ETX)

• DTT Name: Human immunodeficiency virus Reverse transcriptase (HIV RT)
• Synonyms: HIV p66 RT; HIV Exoribonuclease H
• Gene Name: HIV RT
• DTT Type: Successful target; [1]
• Related Disease:
  Hepatitis virus infection [ICD-11: 1E50-1E51]
  Human immunodeficiency virus disease [ICD-11: 1C60-1C62]
  Virus infection [ICD-11: 1A24-1D9Z]
• UniProt ID: POL_HV1B1
• TTD ID: T14342
• EC Number: EC 2.7.7.49
• Sequence:
  PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV
  FAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL
  DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVI
  YQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWT
  VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE
  LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGA
  HTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTP
  PLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQ
  AIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHK
  GIGGNEQVDKLVSAGIRKIL
• Function: Gag-Pol polyprotein: Mediates, with Gag polyprotein, the essential events in virion assembly, including binding the plasma membrane, making the protein-protein interactions necessary to create spherical particles, recruiting the viral Env proteins, and packaging the genomic RNA via direct interactions with the RNA packaging sequence (Psi). Gag-Pol polyprotein may regulate its own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, the polyprotein would promote translation, whereas at high concentration, the polyprotein would encapsidate genomic RNA and then shut off translation.

Molecular Interaction Atlas (MIA) of This DTT

19 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[2]
Adefovir dipivoxil	DMMAWY1	Hepatitis B virus infection	1E51.0	Approved	[3]
Bictegravir, emtricitabine and tenofovir alafenamide	DMG0H8K	Human immunodeficiency virus infection	1C62	Approved	[4]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[3]
Didanosine	DMI2QPE	Human immunodeficiency virus infection	1C62	Approved	[5]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[3]
Emtricitabine	DMBMUWZ	Hepatitis virus infection	1E50-1E51	Approved	[6], [7]
Etravirine	DMGV8QU	Human immunodeficiency virus-1 infection	1C62	Approved	[8]
GS-7340	DM1ECNJ	Hepatitis B virus infection	1E51.0	Approved	[9]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[3]
MK-1439	DM215WE	Human immunodeficiency virus infection	1C62	Approved	[4], [10]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[11]
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[12]
Sorivudine	DMUJGR1	Virus infection	1A24-1D9Z	Approved	[1], [13]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[14]
Tenofovir	DM1IS6U	Human immunodeficiency virus infection	1C62	Approved	[15]
Tenofovir disoproxil fumarate	DMSY4ZG	Discovery agent	N.A.	Approved	[6], [16]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[17], [18]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[15]

35 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apricitabine	DM1K78U	Human immunodeficiency virus infection	1C62	Phase 3	[19]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[20]
Glyminox	DMQCZ4N	Sexually transmitted infection	1A9Z	Phase 3	[21]
PT-304	DMMJ63A	N. A.	N. A.	Phase 3	[22]
VM-1500	DM4WQBO	Human immunodeficiency virus infection	1C62	Phase 2/3	[23]
Alovudine	DMJPV5X	Breast cancer	2C60-2C65	Phase 2	[19]
Amdoxovir	DMEB3T9	Hepatitis B virus infection	1E51.0	Phase 2	[24]
BILR-355	DMAG4SX	Human immunodeficiency virus infection	1C62	Phase 2	[25], [26]
Emivirine	DMQH1NV	Human immunodeficiency virus infection	1C62	Phase 2	[27]
F4co vaccine	DM6UQNW	Human immunodeficiency virus infection	1C62	Phase 2	[28]
IDX899	DMSRC5D	Human immunodeficiency virus infection	1C62	Phase 2	[29]
L-697,661	DMB7WT1	Human immunodeficiency virus infection	1C62	Phase 2	[30]
Lersivirine	DMSEVBH	Human immunodeficiency virus infection	1C62	Phase 2	[31]
Lexipafant	DMZ2YBE	Nerve injury	ND56.4	Phase 2	[12]
OBP-601	DMVXZC4	Human immunodeficiency virus-1 infection	1C62	Phase 2	[32]
RALURIDINE	DMBFZSX	Human immunodeficiency virus infection	1C62	Phase 2	[33], [26]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[34]
Dapivirine	DMJPSIL	Human immunodeficiency virus infection	1C62	Phase 1/2	[12]
Triciribine	DM8IC5H	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[35]
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[34]
AIC-292	DMNHBMC	Human immunodeficiency virus infection	1C62	Phase 1	[36]
ATEVIRDINE	DM96JTX	Human immunodeficiency virus infection	1C62	Phase 1	[37]
Calanolide A	DMQTUH8	Mycobacterium infection	1B10-1B21	Phase 1	[38]
Capravirine	DM9ERH1	Human immunodeficiency virus infection	1C62	Phase 1	[39]
CMX-157	DMMF0J3	Human immunodeficiency virus infection	1C62	Phase 1	[40]
GW-695634	DMBDW93	Human immunodeficiency virus infection	1C62	Phase 1	[41]
KM-023	DME8DUV	Human immunodeficiency virus infection	1C62	Phase 1	[42]
MK-6186	DMSA27Z	Human immunodeficiency virus infection	1C62	Phase 1	[43]
MK-8504	DMHTWBL	Human immunodeficiency virus-1 infection	1C62	Phase 1	[44]
MK-8583	DMQHPME	Human immunodeficiency virus-1 infection	1C62	Phase 1	[45]
MSH-372	DMEP7HO	Human immunodeficiency virus infection	1C62	Phase 1	[46]
PT-112	DMB6M1P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[47]
PT-302	DMWBA1S	N. A.	N. A.	Phase 1	[22]
TROVIRDINE HYDROCHLORIDE	DMDSF0Q	Human immunodeficiency virus infection	1C62	Phase 1	[48]
UC-781	DM5XMHB	Human immunodeficiency virus infection	1C62	Phase 1	[49]

36 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lobucavir	DM8OMI6	Virus infection	1A24-1D9Z	Discontinued in Phase 3	[50]
AZT-P-DDI	DM04CIK	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[51], [26]
DMP-961	DMI5XKC	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[52], [26]
Elvucitabine	DMM5WQL	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[53]
FOZIVUDINE TIDOXIL	DMUD0IN	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[54], [26]
L-696229	DM54I8A	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[55], [26]
Lodenosine	DMGZ3BF	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[56]
Loviride	DMD16VS	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[57]
Opaviraline	DMP0ARJ	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[58]
R-18893	DMGVRQ2	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[59]
DPC-082	DMSOHR6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[60], [26]
L-697639	DMBIR5P	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[61]
LY-73497	DMB1OAR	N. A.	N. A.	Discontinued in Phase 1	[22]
PNU-142721	DMPWG2K	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[62]
R-82150	DMTK3DR	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[63]
R-82913	DM4WJHY	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[64]
A-79296	DM3IYMF	Herpes simplex virus infection	1F00	Terminated	[65]
ANX-201	DMOJP9E	Cytomegalovirus infection	1D82	Terminated	[66]
BAY-Z-4305	DMZGFM6	Human immunodeficiency virus-1 infection	1C62	Terminated	[67]
BEA-005	DM6KRJW	Cytomegalovirus infection	1D82	Terminated	[68]
C-AFG	DMJQ3WR	Virus infection	1A24-1D9Z	Terminated	[69]
DMP-963	DMKU469	Human immunodeficiency virus infection	1C62	Terminated	[52], [26]
DPC-A78277	DM67VDK	Human immunodeficiency virus infection	1C62	Terminated	[70]
GS-9148	DMCYZL3	Human immunodeficiency virus infection	1C62	Terminated	[71]
ISIS-1082	DMD6SXO	Virus infection	1A24-1D9Z	Terminated	[72]
MEN-10690	DM57S3D	Human immunodeficiency virus-1 infection	1C62	Terminated	[73]
MEN-10880	DMKS1W0	Human immunodeficiency virus-1 infection	1C62	Terminated	[73]
MEN-10979	DM6UYN1	Human immunodeficiency virus-1 infection	1C62	Terminated	[74]
MIV-170	DMT9QB5	Human immunodeficiency virus infection	1C62	Terminated	[75]
MSC-204	DMNYLEU	Human immunodeficiency virus infection	1C62	Terminated	[46]
Navuridine	DM8FB6E	Human immunodeficiency virus infection	1C62	Terminated	[76]
RDEA-427	DM08BUV	Human immunodeficiency virus infection	1C62	Terminated	[77]
RDEA-640	DM61RGQ	Human immunodeficiency virus infection	1C62	Terminated	[78]
SPD-756	DM9HFV7	Human immunodeficiency virus infection	1C62	Terminated	[79]
UC-38	DM0Z7PK	Human immunodeficiency virus infection	1C62	Terminated	[80]
UC-84	DMY9UEZ	Human immunodeficiency virus infection	1C62	Terminated	[81]

117 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea	DMER0IY	Discovery agent	N.A.	Investigative	[82]
1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea	DM0K2T1	Discovery agent	N.A.	Investigative	[22]
1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea	DMC1IKP	Discovery agent	N.A.	Investigative	[82]
1-(2-Phenyl-propyl)-3-thiazol-2-yl-thiourea	DMXG10E	Discovery agent	N.A.	Investigative	[22]
1-(2-Pyridin-2-yl-ethyl)-3-thiazol-2-yl-thiourea	DM4B2EN	Discovery agent	N.A.	Investigative	[22]
1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea	DM37RI9	Discovery agent	N.A.	Investigative	[22]
1-(4-Butyl-thiazol-2-yl)-3-phenethyl-thiourea	DMIGDCK	Discovery agent	N.A.	Investigative	[22]
1-(4-Cyano-thiazol-2-yl)-3-phenethyl-thiourea	DM9EK3T	Discovery agent	N.A.	Investigative	[22]
1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea	DM60Y8M	Discovery agent	N.A.	Investigative	[82]
1-Benzenesulfonyl-2-nitro-benzene	DM781L6	Discovery agent	N.A.	Investigative	[83]
1-Benzothiazol-2-yl-3-phenethyl-thiourea	DMEZPC8	Discovery agent	N.A.	Investigative	[22]
1-Benzyl-3-thiazol-2-yl-thiourea	DMNWGOE	Discovery agent	N.A.	Investigative	[22]
1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea	DMF4BCP	Discovery agent	N.A.	Investigative	[82]
1-nitro-2-(2-nitrophenylsulfonyl)benzene	DMP6VOK	Discovery agent	N.A.	Investigative	[83]
1-Phenethyl-3-[1,3,4]thiadiazol-2-yl-thiourea	DM32WSM	Discovery agent	N.A.	Investigative	[22]
1-Thiazol-2-yl-3-(2-o-tolyl-ethyl)-thiourea	DMAQKO1	Discovery agent	N.A.	Investigative	[22]
1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea	DMCIA40	Discovery agent	N.A.	Investigative	[82]
10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	DM1JLUV	Discovery agent	N.A.	Investigative	[84]
10-Ethyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	DMGT82V	Discovery agent	N.A.	Investigative	[84]
10-Isopropyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	DMCXA1Y	Discovery agent	N.A.	Investigative	[84]
10-Propyl-10H-dibenzo[b,f][1,4]oxazepin-11-one	DMD1258	Discovery agent	N.A.	Investigative	[84]
10-Propyl-10H-dibenzo[b,f][1,4]thiazepin-11-one	DMZ3N8A	Discovery agent	N.A.	Investigative	[84]
2',3'-ddATP	DMOB7P6	Discovery agent	N.A.	Investigative	[85]
2'-3'-dideoxy-7-deaza-guaninetriphosphate	DM74X5O	Discovery agent	N.A.	Investigative	[85]
2'-deoxythymidine triphosphate	DM9OEJT	Discovery agent	N.A.	Investigative	[85]
2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile	DM3VJEZ	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile	DMFW9D3	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(2-chloro-phenylsulfanyl)-benzonitrile	DM7391H	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(2-cyano-benzenesulfinyl)-benzonitrile	DM8O6AC	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(2-cyano-benzenesulfonyl)-benzonitrile	DMRKQLV	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(2-cyano-phenylsulfanyl)-benzonitrile	DM8UQD5	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile	DMBMK8S	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(2-methoxy-phenylsulfanyl)-benzonitrile	DM0N5J4	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-bromo-benzenesulfinyl)-benzonitrile	DM6R98Y	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile	DMTUM78	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-bromo-phenylsulfanyl)-benzonitrile	DMH4TRD	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile	DM9XKJQ	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-chloro-phenylsulfanyl)-benzonitrile	DMT3KP0	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-cyano-benzenesulfonyl)-benzonitrile	DM9GQ1U	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-cyano-phenylsulfanyl)-benzonitrile	DM2MCK1	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-fluoro-phenylsulfanyl)-benzonitrile	DMG7HP2	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(3-methoxy-phenylsulfanyl)-benzonitrile	DMACYWZ	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(4-chloro-phenylsulfanyl)-benzonitrile	DML6EFV	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(naphthalene-1-sulfonyl)-benzonitrile	DMXPWHF	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(naphthalene-2-sulfonyl)-benzonitrile	DMMKJYG	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(toluene-2-sulfonyl)-benzonitrile	DMWGE3U	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(toluene-3-sulfinyl)-benzonitrile	DMJXWH0	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(toluene-3-sulfonyl)-benzonitrile	DM1EGP9	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-(toluene-4-sulfonyl)-benzonitrile	DMB7415	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-benzenesulfonyl-benzonitrile	DMJ4H9F	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-m-tolylsulfanyl-benzonitrile	DMQF9H1	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-p-tolylsulfanyl-benzonitrile	DM4BQ1W	Discovery agent	N.A.	Investigative	[83]
2-Amino-6-phenylsulfanyl-benzonitrile	DMMBGK0	Discovery agent	N.A.	Investigative	[83]
2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine	DM6F0C4	Discovery agent	N.A.	Investigative	[86]
3'thiacytidine	DM2K59V	Discovery agent	N.A.	Investigative	[18]
3-Benzylamino-5-ethyl-6-methyl-1H-pyridin-2-one	DMB4WP5	Discovery agent	N.A.	Investigative	[87]
6-Benzyl-2-cyclohexylsulfanyl-3H-pyrimidin-4-one	DM0CZ1F	Discovery agent	N.A.	Investigative	[88]
6-Benzyl-2-cyclopentylsulfanyl-3H-pyrimidin-4-one	DMZRQEF	Discovery agent	N.A.	Investigative	[89]
6-Benzyl-2-isobutylsulfanyl-3H-pyrimidin-4-one	DMI5RNJ	Discovery agent	N.A.	Investigative	[88]
6-Benzyl-2-sec-butylsulfanyl-3H-pyrimidin-4-one	DM7ANE3	Discovery agent	N.A.	Investigative	[89]
Benzimidazole 5-carboxamide	DM75U9X	Hepatovirus infection	1E51	Investigative	[12]
CORILAGIN	DMAC698	Discovery agent	N.A.	Investigative	[90]
Deoxyfluorothymidine	DMKFMRY	Discovery agent	N.A.	Investigative	[18]
Dihydropyrone	DMYSPMH	Hepatovirus infection	1E51	Investigative	[12]
E-EBU-dM	DMN8JKX	Discovery agent	N.A.	Investigative	[91]
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate	DM3FH02	Discovery agent	N.A.	Investigative	[92]
Ethyl 1-[(1H-benzimidazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate	DMQ0XYH	Discovery agent	N.A.	Investigative	[92]
Ethyl 1-[(1H-benzotriazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate	DM82X3J	Discovery agent	N.A.	Investigative	[92]
HEPT	DMK846H	Discovery agent	N.A.	Investigative	[93]
HI-172	DMCKAWY	Discovery agent	N.A.	Investigative	[94]
HI-236	DM3R4ZF	Discovery agent	N.A.	Investigative	[95]
HI-240	DMQK5RM	Discovery agent	N.A.	Investigative	[96]
HI-241	DMTKCW6	Discovery agent	N.A.	Investigative	[95]
HI-242	DM0QYLP	Discovery agent	N.A.	Investigative	[95]
HI-244	DMG36BD	Discovery agent	N.A.	Investigative	[82]
HI-280	DME4SML	Discovery agent	N.A.	Investigative	[94]
HI-281	DM7K0PH	Discovery agent	N.A.	Investigative	[94]
HI-443	DMSUWD8	Discovery agent	N.A.	Investigative	[96]
HI-445	DMYP0DE	Discovery agent	N.A.	Investigative	[94]
Indole N -acetamide	DMEHI15	Hepatovirus infection	1E51	Investigative	[12]
ISODISPAR B	DM7ZSVD	Discovery agent	N.A.	Investigative	[97]
NSC-380292	DMHO40Q	Discovery agent	N.A.	Investigative	[98]
NSC-625487	DM63G4R	Human immunodeficiency virus infection	1C62	Investigative	[99], [26]
PT-101	DM47F9I	Discovery agent	N.A.	Investigative	[22]
PT-102	DMD0K61	Discovery agent	N.A.	Investigative	[95]
PT-103	DM0LTB2	Discovery agent	N.A.	Investigative	[22]
PT-104	DMABLF7	Discovery agent	N.A.	Investigative	[47]
PT-106	DMPX71O	Discovery agent	N.A.	Investigative	[22]
PT-108	DMBLAV4	Discovery agent	N.A.	Investigative	[22]
PT-109	DM8PX1T	Discovery agent	N.A.	Investigative	[47]
PT-110	DMEIW5T	Discovery agent	N.A.	Investigative	[47]
PT-113	DMUFC6V	Discovery agent	N.A.	Investigative	[47]
PT-114	DMYE1P8	Discovery agent	N.A.	Investigative	[47]
PT-115	DMS01IN	Discovery agent	N.A.	Investigative	[47]
PT-306	DME0N2Z	Discovery agent	N.A.	Investigative	[22]
PT-307	DM45HVR	Discovery agent	N.A.	Investigative	[22]
PT-308	DM7FM8V	Discovery agent	N.A.	Investigative	[22]
PT-309	DM7TILD	Discovery agent	N.A.	Investigative	[22]
PT-310	DMT7G32	Discovery agent	N.A.	Investigative	[22]
PT-311	DM9ZCGX	Discovery agent	N.A.	Investigative	[22]
PT-312	DM7GN3E	Discovery agent	N.A.	Investigative	[22]
PT-313	DMN80XD	Discovery agent	N.A.	Investigative	[22]
PT-314	DM5C1ND	Discovery agent	N.A.	Investigative	[22]
PT-315	DMUK7IT	Discovery agent	N.A.	Investigative	[22]
PT-316	DMXM6NT	Discovery agent	N.A.	Investigative	[22]
PT-317	DM14XB7	Discovery agent	N.A.	Investigative	[22]
PT-319	DMKEPGN	Discovery agent	N.A.	Investigative	[22]
PT-320	DMV940C	Discovery agent	N.A.	Investigative	[22]
PT-322	DMIHSEV	Discovery agent	N.A.	Investigative	[22]
R-87027	DM2QN0S	Discovery agent	N.A.	Investigative	[100]
RTI-20	DMD3ST8	Discovery agent	N.A.	Investigative	[101]
Tetrahydroimidazo[4,5,1-jk]-[1,4]benzodiazepin-2(1H)-one	DMNH3ST	Discovery agent	N.A.	Investigative	[102]
TNK-651	DMC958O	Discovery agent	N.A.	Investigative	[103]
UK-129485	DM6GLSF	Discovery agent	N.A.	Investigative	[104]
[(40-OH) MeLeu]4-CsA derivatives	DM9YHA7	Discovery agent	N.A.	Investigative	[105]
[(40-OH)MeLeu]4-Cyclosporin A	DM1ZM5R	Discovery agent	N.A.	Investigative	[105]
[(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A	DMV30N2	Discovery agent	N.A.	Investigative	[105]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304.
• [6] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [7] Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today (Barc). 2005 Apr;41(4):241-52.
• [8] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020
• [10] Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett. 2014 Feb 1;24(3):917-22.
• [11] HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
• [12] Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
• [13] New antivirals with activity against varicella-zoster virus. Ann Neurol. 1994;35 Suppl:S69-72.
• [14] Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705.
• [15] Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
• [16] Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther. 2002 Oct;24(10):1515-48.
• [17] A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
• [18] Current use of anti-HIV drugs in AIDS. J Antimicrob Chemother. 1993 Jul;32 Suppl A:133-8.
• [19] Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38.
• [20] Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2763-7.
• [21] Glyminox Biosyn. Curr Opin Investig Drugs. 2004 Feb;5(2):222-31.
• [22] Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
• [23] 127 afety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients. J Acquir Immune Defic Syndr. 2014 April; 65(Suppl 2): 52.
• [24] Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11(5):619-23.
• [25] Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8.
• [26] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [27] Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.Clin Ther.2009 Apr;31(4):692-704.
• [28] EP patent application no. 2621528, Vaccine.
• [29] Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761).Antivir Ther.2014;19(1):69-78.
• [30] Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus ty... FEBS Lett. 1995 Feb 13;359(2-3):233-8.
• [31] Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther.2010 Oct;32(11):1889-95.
• [32] Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8.
• [33] 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603.
• [34] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [35] Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-... J Med Chem. 2005 Jun 2;48(11):3840-51.
• [36] In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9.
• [37] Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum ... J Med Chem. 1996 Sep 13;39(19):3769-89.
• [38] Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. BETA. 1999 Apr;12(2):8-9.
• [39] Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98.
• [40] Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol. 2012 Autumn; 9(3): e183-e193.
• [41] Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35.
• [42] Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects. Drug Des Devel Ther. 2014 Sep 26;8:1613-9.
• [43] Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35.
• [44] ClinicalTrials.gov (NCT03188523) Activity of MK-8504 in Anti-retroviral-naive, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002). U.S. National Institutes of Health.
• [45] ClinicalTrials.gov (NCT03552536) MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002). U.S. National Institutes of Health.
• [46] WO patent application no. 2004,0290,42, Pyrazole derivatives as reverse transcriptase inhibitors.
• [47] Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74.
• [48] Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives tr... Antiviral Res. 1995 Dec;28(4):331-42.
• [49] The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79(17):11179-86.
• [50] Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatit... Antiviral Res. 2000 Dec;48(3):197-203.
• [51] Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral Res. 1996 Jun;31(1-2):115-20.
• [52] Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer. AAPS PharmSciTech. 2000 December; 1(4): 55-61.
• [53] Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.Antimicrob Agents Chemother.2009 Feb;53(2):662-9.
• [54] Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection. J Vet Intern Med. 2011 May-Jun;25(3):413-8.
• [55] L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.. Antimicrob Agents Chemother. 1992 May; 36(5): 1019-1023.
• [56] 2 ,3 -Dialdehyde of ATP, ADP, and adenosine inhibit HIV-1 reverse transcriptase and HIV-1 replication. Curr HIV Res. 2014;12(5):347-58.
• [57] Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7.
• [58] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [59] EP patent application no. 0767664, Combination therapy for hiv infection.
• [60] Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999 Dec;43(12):2893-7.
• [61] Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor. Int J Clin Pharmacol Res. 1994;14(2):45-50.
• [62] Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721. Protein Sci. 2011 Oct;20(10):1713-9.
• [63] Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepin... J Biol Chem. 1991 Aug 5;266(22):14232-6.
• [64] A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991 Oct;16(3):257-66.
• [65] US patent application no. 5,830,759, Unique associated kaposi's sarcoma virus sequences and uses thereof.
• [66] DOI: 10.1038/scibx.2008.591
• [67] US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases.
• [68] Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2). J Virol. 2000 October; 74(20): 9771-9775.
• [69] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003394)
• [70] The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab Dispos. 2004 Dec;32(12):1359-69.
• [71] Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009 Jan;53(1):150-6.
• [72] Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology. 1997 Jan 15;116(1-3):77-88.
• [73] US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
• [74] New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res. 1996 May;30(2-3):109-24.
• [75] Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem Pharmacol. 2010 Oct 15;80(8):1133-40.
• [76] Synthesis and anti-human immunodeficiency virus (HIV-1) activity of 3'-deoxy-3'-(triazol-1-yl)thymidines and 2',3'-dideoxy-3'-(triazol-1-yl)uridines and inhibition of reverse transcriptase by their 5'-triphosphates. Chem Pharm Bull (Tokyo). 1990 Sep;38(9):2597-601.
• [77] CN patent application no. 103360398, Triazolopyrimidine hiv-1 retrovirus inhibitor and its preparation method and application thereof.
• [78] WO patent application no. 2008,0165,22, Novel hiv reverse transcriptase inhibitors.
• [79] Single dose pharmacokinetics of SPD-756 in healthy adult volunteers, P F Smith, Poster Exhibition: The XIV International AIDS Conference: Abstract no. WePeB6050.
• [80] Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Ther. 1996 Jan;276(1):298-305.
• [81] Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry. 1998 Oct 13;37(41):14394-403.
• [82] Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8.
• [83] 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82.
• [84] Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97.
• [85] Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcript... J Med Chem. 2005 Apr 7;48(7):2695-700.
• [86] Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. J Med Chem. 1998 Sep 24;41(20):3793-803.
• [87] Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one. J Med Chem. 1992 Oct 16;35(21):3792-802.
• [88] Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J Med Chem. 1995 Aug 18;38(17):3258-63.
• [89] 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine d... J Med Chem. 1999 Feb 25;42(4):619-27.
• [90] HIV and reverse transcriptase inhibition by tanninsOriginal Research. Bioorg. Med. Chem. Lett. 2(12):1529-1534 (1992).
• [91] Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor. Microbiol Immunol. 1998;42(3):195-202.
• [92] Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg Med Chem. 2000 Sep;8(9):2305-9.
• [93] 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S... Bioorg Med Chem Lett. 2004 Jun 21;14(12):3173-6.
• [94] Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8.
• [95] Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90.
• [96] N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency vi... Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-6.
• [97] 4-Phenylcoumarins as HIV transcription inhibitors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4447-50.
• [98] New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity. Bioorg Med Chem Lett. 2006 Jun 1;16(11):3034-8.
• [99] Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir Chem Chemother. 1999 Jul;10(4):211-7.
• [100] Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. J Med Chem. 1998 Dec 17;41(26):5272-86.
• [101] Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J Med Chem. 1991 Jul;34(7):2231-41.
• [102] Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9878-82.
• [103] Synthesis and Antiviral Evaluation of 1-[(2-Phenoxyethyl)oxymethyl] and 6-(3,5-Dimethoxybenzyl) Analogues of HIV Drugs Emivirine and TNK-651.Drug Res (Stuttg).2016 Apr;66(4):181-8.
• [104] Imidazo[2 3 :6,5]dipyrido[3,2-b:2 3 e]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine, Bioorg. Med. Chem. Lett. 2(12):1745-1750(1992).
• [105] Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9.